4D Molecular Therapeutics Inc
$ 11.19
4.58%
04 Dec - close price
- Market Cap 639,342,000 USD
- Current Price $ 11.19
- High / Low $ 11.40 / 10.54
- Stock P/E N/A
- Book Value 7.89
- EPS -3.75
- Next Earning Report 2026-02-27
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.45 %
- 52 Week High 12.34
- 52 Week Low 2.23
About
4D Molecular Therapeutics, Inc. is a cutting-edge clinical-stage gene therapy company based in Emeryville, California, specializing in the development of innovative therapeutics through its proprietary adeno-associated virus (AAV) vector platform. Focused on addressing significant unmet medical needs in ophthalmology, neurology, and rare diseases, the company is committed to transforming patient outcomes with its advanced gene therapies. With a robust pipeline and strategic partnerships, 4D Molecular Therapeutics is well-positioned to lead the biotherapeutics sector and drive the commercialization of novel treatments, enhancing its standing as a key player in the biotechnology landscape.
Analyst Target Price
$33.11
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-11 | 2025-05-07 | 2025-02-26 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-29 | 2023-11-09 | 2023-08-09 | 2023-05-10 | 2023-03-15 |
| Reported EPS | -1.01 | -0.98 | -0.86 | -0.9 | -0.79 | -0.63 | -0.66 | -0.75 | -0.24 | -0.77 | -0.88 | -0.84 |
| Estimated EPS | -1.01 | -0.73 | -0.8621 | -0.8379 | -0.7 | -0.7 | -0.74 | -0.74 | -0.59 | -0.81 | -0.89 | -0.79 |
| Surprise | 0 | -0.25 | 0.0021 | -0.0621 | -0.09 | 0.07 | 0.08 | -0.01 | 0.35 | 0.04 | 0.01 | -0.05 |
| Surprise Percentage | 0% | -34.2466% | 0.2436% | -7.4114% | -12.8571% | 10% | 10.8108% | -1.3514% | 59.322% | 4.9383% | 1.1236% | -6.3291% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-27 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.532 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: FDMT
2025-11-02 11:06:01
4D Molecular Therapeutics (FDMT) is proceeding with late-stage eye drug trials for 4D-150, despite increased quarterly losses of $54.7 million and a 25% workforce reduction to extend its financial runway through 2028. The company is buoyed by positive SPECTRA study results for diabetic macular edema and optimistic analyst sentiment, with a consensus 'buy' rating and a $30 price target, significantly higher than its August closing price. Regulatory engagement with the FDA and EMA continues, positioning 4D Molecular Therapeutics to potentially advance gene therapies into mainstream medical care for age-related and chronic conditions.
2025-10-18 06:15:35
Leerink Partners has issued an optimistic estimate for 4D Molecular Therapeutics (FDMT) earnings, projecting $0.05 EPS for the third quarter of 2025 and $0.18 EPS for the full fiscal year. This comes as institutional investors have significantly increased their holdings in the company, which develops genetic medicines across ophthalmology, cardiology, and pulmonology.
2025-10-17 20:05:00
4D Molecular Therapeutics (4DMT) announced the grant of 25,450 Restricted Stock Units (RSUs) to three new non-executive employees on October 14, 2025, under its 2025 Employment Inducement Award Plan. This plan was approved to attract new talent and complies with Nasdaq Global Market rules for employment inducement equity grants. 4DMT is a late-stage biotechnology company focused on advancing disease-targeted therapeutics, with lead product candidates like 4D-150 for retinal diseases and 4D-710 for cystic fibrosis in clinical development.
2025-10-17 20:05:00
4D Molecular Therapeutics announced the grant of 25,450 Restricted Stock Units (RSUs) to three new non-executive employees on October 14, 2025. These grants were made under the Company’s 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company focusing on gene therapies for diseases like wet age-related macular degeneration and cystic fibrosis.
2025-10-17 20:05:00
4D Molecular Therapeutics (Nasdaq: FDMT) announced that its compensation committee granted 25,450 Restricted Stock Units (RSUs) to three new non-executive employees on October 14, 2025, under its 2025 Employment Inducement Award Plan. This plan, approved in February 2025, is used to attract new hires according to Nasdaq Rule 5635(c)(4). The announcement did not disclose recipient names, vesting terms, or the share-count impact.
2025-10-17 15:02:27
Wall Street analysts project a 208.5% upside for 4D Molecular Therapeutics (FDMT), with a mean price target of $31.13. Despite the potential for over-optimistic price targets due to business incentives, a low standard deviation in estimates suggests a high degree of agreement among analysts. The stock's positive trend in earnings estimate revisions and a Zacks Rank #2 (Buy) further support a potential upside.
